natgillin/translations-raw huggingface dataset:
The European Medicines Agency has deferred the obligation to submit the results of studies with Procoralan in one or more subsets of the paediatric population in the treatment of chronic heart failure (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila obvezo za predložitev rezultatov študij z zdravilom Procoralan za eno ali več podskupin pediatrične populacije za zdravljenje kroničnega srčnega popuščanja (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Other medicines and Procoralan 
Druga zdravila in zdravilo Procoralan
Procoralan may cause temporary luminous visual phenomena (a temporary brightness in the field of vision, see “Possible side effects”). 
Procoralan lahko povzroča začasne vidne pojave svetlikanja (prehodno povečanje svetlosti v vidnem polju, glejte “Možni neželeni učinki”).
Elevated creatinine in blood ECG prolonged QT interval 
Preiskave občasni povečanje kreatinina v krvi podaljšanje intervala QT na EKG
How does Procoralan work? 
Kako deluje zdravilo Procoralan?
Ivabradine does not influence intracardiac conduction, contractility (no negative inotropic effect) or ventricular repolarisation: 
Ivabradin ne vpliva na znotrajsrčno prevajanje, kontraktilnost (ni negativnega inotropnega učinka) ali repolarizacijo prekatov:
Do not take Procoralan - if you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section 
Kaj morate vedeti, preden boste vzeli zdravilo Procoralan Ne jemljite zdravila Procoralan če ste alergični na ivabradin ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Procoralan 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening. 
Nekaterim bolnikom (na primer, če ste starejši) lahko zdravnik predpiše polovični odmerek, se pravi eno polovico 5 mg tablete (kar ustreza 2,5 mg ivabradina) zjutraj in eno polovico 5 mg tablete zvečer.
Procoralan contains lactose 
Zdravilo Procoralan vsebuje laktozo.
The starting dose should not exceed one tablet of Procoralan 5 mg twice daily. 
Začetni odmerek ne sme presegati ene tablete zdravila Procoralan 5 mg dvakrat na dan.
Do not take Procoralan if you are able to become pregnant unless you use reliable contraceptive measures (see “Do not take Procoralan”). 
Če ste ženska v rodni dobi ne smete jemati zdravila Procoralan, razen če uporabljate zanesljive kontracepcijske metode (glejte “Ne jemljite zdravila Procoralan”).
Palpitations and cardiac extra beats, feeling sick (nausea), constipation, diarrhoea, abdominal pain, spinning sensation (vertigo), difficulty breathing (dyspnoea), muscle cramps, changes in laboratory parameters : high blood levels of uric acid, an excess of eosinophils (a type of white blood cell) and elevated creatinine in blood (a breakdown product of muscle), skin rash, angioedema (such as swollen face, tongue or throat, difficulty in breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal ECG heart tracing, double vision, impaired vision. 
Palpitacije in dodatni srčni utripi, občutek slabosti (navzea), zaprtje, driska, bolečina v trebuhu, občutek vrtoglavosti (vertigo), oteženo dihanje (dispneja), mišični krči, spremembe laboratorijskih parametrov: visoke vrednosti sečne kisline v krvi, preveliko število eozinofilcev (vrsta belih krvnih celic) in povečanje kreatinina v krvi (razgradni produkt mišic), kožni izpuščaj, angioedem (kot je otečen obraz, jezik ali grlo, težave pri dihanju ali požiranju), nizek krvni tlak, omedlevica, občutek utrujenosti, občutek šibkosti, nepravilnosti v zapisu EKG srca, dvojni vid, okvara vida.
The usual recommended starting dose is one tablet of Procoralan 5 mg twice daily increasing if necessary to one tablet of Procoralan 7.5 mg twice daily. 
Običajen priporočljiv začetni odmerek je ena tableta zdravila Procoralan 5 mg dvakrat na dan, kar lahko povečate na eno tableto zdravila Procoralan 7,5 mg dvakrat na dan, če je potrebno.
If you forget to take Procoralan: 
Če ste pozabili vzeti zdravilo Procoralan
INFORMATION IN BRAILLE PROCORALAN 5 mg 
PODATKI V BRAILLOVI PISAVI PROCORALAN 5 mg
Do not take Procoralan if you are breast-feeding (see “Do not take Procoralan”). 
Ne jemljite zdravila Procoralan, če dojite (glejte “Ne jemljite zdravila Procoralan”).
MARKETING AUTHORISATION NUMBER(S) EU/1/05/316/001-007 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/05/316/001-007
* Frequency calculated from clinical trials for adverse events detected from spontaneous report 
*Pogostnost neželenih učinkov iz spontanega poročanja je izračunana na podlagi podatkov iz kliničnih študij Opis izbranih neželenih učinkov
MARKETING AUTHORISATION NUMBER(S) EU/1/05/316/008-014 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/05/316/008-014
INFORMATION IN BRAILLE PROCORALAN 7.5 mg 
PODATKI V BRAILLOVI PISAVI PROCORALAN 7,5 mg
Procoralan with food and drink Avoid grapefruit juice during treatment with Procoralan. 
Med zdravljenjem z zdravilom Procoralan se izogibajte uživanju grenivkinega soka.
How to take Procoralan 
Kako jemati zdravilo Procoralan
5 How to store Procoralan Contents of the pack and other information 
Shranjevanje zdravila Procoralan Vsebina pakiranja in dodatne informacije
As the treatment for angina or chronic heart failure is usually life-long, you should discuss with your doctor before stopping this medicinal product. 
Če ste prenehali jemati zdravilo Procoralan Ker je zdravljenje angine pektoris ali kroničnega srčnega popuščanja običajno doživljenjsko, se pred prenehanjem jemanja tega zdravila posvetujte z zdravnikom.
A large dose of Procoralan could make you feel breathless or tired because your heart slows down too much. 
Če ste vzeli večji odmerek zdravila Procoralan, kot bi smeli Velik odmerek zdravila Procoralan bi lahko povzročil zasoplost ali utrujenost, ker preveč upočasni srce.
Very Rare 
Zelo redki:
The European Medicines Agency has waived the obligation to submit the results of studies with Procoralan in all subsets of the paediatric population in the treatment of angina pectoris. 
Procoralan za vse podskupine pediatrične populacije za zdravljenje angine pektoris.
D CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA • Načrt za obvladovanje tveganja (RMP)
Procoralan 7.5 mg tablets are salmon-coloured, triangular, film-coated tablets engraved with “7.5” on one face and on the other. 
Tablete zdravila Procoralan 7,5 mg so lososove barve, trikotne in filmsko obložene, z zarezo na obeh straneh in vrezano oznako “7.5” na eni ter na drugi strani.
What Procoralan contains - The active substance is ivabradine (as hydrochloride). 
- Zdravilna učinkovina je ivabradin (v obliki klorida).
NAME OF THE MEDICINAL PRODUCT Procoralan 5 mg film-coated tablets 
IME ZDRAVILA Procoralan 5 mg filmsko obložene tablete
NAME OF THE MEDICINAL PRODUCT Procoralan 7.5 mg film-coated tablets 
IME ZDRAVILA Procoralan 7,5 mg filmsko obložene tablete
- if your resting heart rate before treatment is too slow (below 70 beats per minute); - if you are suffering from cardiogenic shock (a heart condition treated in hospital); - if you suffer from a heart rhythm disorder; - if you are having a heart attack; - if you suffer from very low blood pressure; - if you suffer from unstable angina (a severe form in which chest pain occurs very frequently and with or without exertion); - if you have heart failure which has recently become worse; - if your heart beat is exclusively imposed by your pacemaker; - if you suffer from severe liver problems; - if you are already taking medicines for the treatment of fungal infections (such as ketoconazole, 
če imate kardiogeni šok (bolezen srca, ki zahteva zdravljenje v bolnišnici); če imate motnje srčnega ritma; če imate miokardni infarkt; če imate zelo nizek krvni tlak; če imate nestabilno angino pektoris (hudo obliko, pri kateri se bolečine v prsih pojavljajo zelo pogosto, med naporom ali brez njega);
Do not take Procoralan if you are pregnant or are planning to have a baby (see “Do not take Procoralan”). 
Nosečnost in dojenje Ne jemljite zdravila Procoralan, če ste noseči ali če načrtujete nosečnost (glejte “Ne jemljite zdravila
The following adverse reactions have been reported during clinical trials and are ranked using the following frequency: very common (≥1/10); common (≥1/100 to, <1/10); uncommon (≥1/1,000 to, <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). 
zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do
Procoralan 7.5 mg: one film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride). 
Procoralan 7,5 mg: ena filmsko obložena tableta vsebuje 7,5 mg ivabradina (kar ustreza 8,085 mg ivabradinijevega klorida).
Procoralan 5 mg: one film-coated tablet contains 5 mg ivabradine (equivalent to 5.390 mg ivabradine as hydrochloride). 
Procoralan 5 mg: ena filmsko obložena tableta vsebuje 5 mg ivabradina (kar ustreza 5,390 mg ivabradinijevega klorida).
What Procoralan looks like and contents of the pack Procoralan 5 mg tablets are salmon-coloured, oblong film-coated tablets scored on both sides, engraved with “5” on one face and on the other. 
Tablete zdravila Procoralan 5 mg so lososove barve, podolgovate in filmsko obložene, z zarezo na obeh straneh in vrezano oznako “5” na eni ter na drugi strani.
Talk to your doctor or pharmacist before taking Procoralan - if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality of electrocardiogram (ECG) called ‘long QT syndrome', - if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much), - if you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats per minute) or irregular, without any apparent reason, making it difficult to measure), - if you have had a recent stroke (cerebral attack), - if you suffer from mild to moderate low blood pressure, - if you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive treatment, - if you suffer from severe heart failure or heart failure with abnormality of ECG called ‘bundle branch block', - if you suffer from chronic eye retinal disease, - if you suffer from moderate liver problems, - if you suffer from severe renal problems. 
če opažate simptome, kot so utrujenost, vrtoglavost ali zasoplost (to bi lahko pomenilo, da se vaše srce preveč upočasnjuje); če imate simptome atrijske fibrilacije (nenavadno visok srčni utrip v mirovanju (nad 110 utripov na minuto) ali brez posebnega vzroka nereden srčni utrip, ki ga je težko izmeriti); če ste nedavno imeli možgansko kap (možganski napad); če imate blago do zmerno znižan krvni tlak;
Talk to your doctor if you are breast-feeding or intending to breast-feed as breastfeeding should be discontinued if you take Procoralan. 
Če dojite ali nameravate dojiti se posvetujte z zdravnikom, ker morate z dojenjem prekiniti, če jemljete zdravilo
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Resting heart rate below 70 beats per minute prior to treatment - Cardiogenic shock - Acute myocardial infarction - Severe hypotension (< 90/50 mmHg) - Severe hepatic insufficiency - Sick sinus syndrome - Sino-atrial block - Unstable or acute heart failure - Pacemaker dependent (heart rate imposed exclusively by the pacemaker) - Unstable angina - AV-block of 3rd degree - Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals 
hudo jetrno popuščanje sindrom bolnega sinusnega vozla sinoatrijski blok nestabilno ali akutno srčno popuščanje odvisnost od srčnega spodbujevalnika (srčna frekvenca, ki jo narekuje izključno srčni spodbujevalnik) nestabilna angina pektoris atrioventrikularni blok 3. stopnje kombinacija z močnimi zaviralci citokroma P450 3A4, kot so azolski antimikotiki (ketokonazol, itrakonazol), makrolidni antibiotiki (klaritromicin, eritromicin peroralno, josamicin, telitromicin), zaviralci proteaze virusa HIV (nelfinavir, ritonavir) in nefazodon (glejte poglavji 4.5 in 5.2) kombinacija z verapamilom ali diltiazemom, zmernima zaviralcema citokroma P450 3A4, ki imata lastnosti zniževanja srčne frekvence (glejte poglavje 4.5)
Ivabradine is indicated : - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta blocker dose. 
Ivabradin je indiciran: pri odraslih, pri katerih so antagonisti adrenergičnih receptorjev beta kontraindicirani ali jih ne prenašajo,
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets ivabradine 
Procoralan 7,5 mg filmsko obložene tablete ivabradin
NAME OF THE MEDICINAL PRODUCT Procoralan 5 mg film-coated tablets ivabradine 
Procoralan 5 mg filmsko obložene tablete ivabradin
How to store Procoralan 
Shranjevanje zdravila Procoralan
Procoralan (ivabradine) is a heart medicine used to treat: - Symptomatic stable angina pectoris (which causes chest pain) in adult patients whose heart rate is over or equal to 70 beats per minute. 
Kaj je zdravilo Procoralan in za kaj ga uporabljamo Procoralan (ivabradin) je zdravilo za srce, namenjeno za zdravljenje: simptomatske stabilne angine pektoris (bolezen, ki povzroča bolečine v prsih) pri odraslih bolnikih,
The following adverse reactions have been reported during clinical trials and are ranked using the following frequency: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). 
<1/1.000); zelo redki (<1/10.000); neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
The study demonstrated a clinically and statistically significant relative risk reduction of 18% in the rate of the primary composite endpoint of cardiovascular mortality and hospitalisation for worsening heart failure (hazard ratio: 0.82, 95%CI [0.75;0.90] - p<0.0001) apparent within 3 months of initiation of treatment. 
(razmerje tveganja: 0,82, 95 % interval zaupanja [0,75;0,90] - p<0,0001), vidnega po 3 mesecih po začetku zdravljenja.
itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin or erythromycin given orally), medicines to treat HIV infections (such as nelfinavir, ritonavir) or nefazodone (medicine to treat depression) or diltiazem, verapamil (used for high blood pressure or angina pectoris); - if you are a woman able to have children and not using reliable contraception; - if you are pregnant or trying to become pregnant; - if you are breast-feeding. 
če imate srčno popuščanje, ki se je pred kratkim poslabšalo; če vam srčni utrip narekuje izključno vaš srčni spodbujevalnik; če imate hude težave z jetri; če že jemljete zdravila proti glivičnim okužbam (na primer ketokonazol, itrakonazol), makrolidne antibiotike (na primer josamicin, klaritromicin, telitromicin ali eritromicin peroralno), zdravila proti okužbam z virusom HIV (na primer nelfinavir, ritonavir) ali nefazodon (zdravilo proti depresiji) ali diltiazem, verapamil (uporabljata se za zniževanje krvnega tlaka oz. zdravljenje angine pektoris);
- in clinical electrophysiology studies, ivabradine had no effect on atrioventricular or intraventricular conduction times or corrected QT intervals; 
- v kliničnih elektrofizioloških študijah ivabradin ni vplival na čase atrioventrikularnega ali intraventrikularnega prevajanja ali na interval QT s popravkom; - pri bolnikih z disfunkcijo levega prekata (iztisnim deležem levega prekata med 30 in 45 %) ivabradin ni imel nobenih škodljivih učinkov na iztisni delež levega prekata.
United Kingdom Servier Laboratories Ltd Tel: +44 (0)1 753 666409 
Tel: +44 (0)1 753 666409
conducted in 6505 adult patients with stable chronic CHF (for ≥ 4 weeks), NYHA class II to IV, with a reduced left ventricular ejection fraction (LVEF ≤ 35%) and a resting heart rate ≥ 70 bpm. 
z zmanjšanim iztisnim deležem levega prekata (LVEF ≤ 35 %) in srčno frekvenco v mirovanju ≥ 70
The SHIFT study was a large multicentre, international, randomised double-blind placebo controlled outcome trial. 
V združeni analizi vseh dvojno slepih nadzorovanih kliničnih preskušanj II.
- in patients with left ventricular dysfunction (left ventricular ejection fraction (LVEF) between 30 
- Bolniki z jetrnim popuščanjem: pri bolnikih z blagim jetrnim popuščanjem (Child-Pughov seštevek do
Immediate Packaging Pack size 
Farmacevtska oblika Stična ovojnina Ovojnina
The infusion should last around 15 minutes. 
Infundiranje traja približno 15 minut.
The European Commission granted a marketing authorisation valid throughout the European Union for Respreeza on 20 August 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Respreeza, veljavno po vsej Evropski uniji, izdala 20. avgusta 2015.
What measures are being taken to ensure the safe and effective use of Respreeza? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Respreeza?
Other information about Respreeza 
Druge informacije o zdravilu Respreeza
The full EPAR for Respreeza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Respreeza je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Allergic reactions have been observed during treatment, some of which were severe. 
Med zdravljenjem so opazili alergijske reakcije, od katerih so bile nekatere hude.
The company that markets Respreeza will carry out a further study to assess whether an increased dose of 120 mg/kg may lead to improved effects compared with the currently recommended dose. 
Družba, ki trži zdravilo Respreeza, bo izvedla dodatno študijo, s katero bo ocenila, ali lahko višji odmerek 120 mg/kg izboljša njegove učinke v primerjavi s trenutno priporočenim odmerkom.
The recommended dose of Respreeza is 60 mg per kilogram body weight, given once a week. 
Priporočeni odmerek zdravila Respreeza je 60 mg na kilogram telesne mase, ki se daje enkrat na teden.
No other major concerns have been identified about the safety of the medicine. 
Z vidika varnosti pri tem zdravilu niso ugotovili nobenih drugih večjih zadržkov.
This is a summary of the European public assessment report (EPAR) for Respreeza. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Respreeza.
What benefits of Respreeza have been shown in studies? 
Kakšne koristi je zdravilo Respreeza izkazalo v študijah?
Therefore, the Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Respreeza's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zato zaključil, da so koristi zdravila Respreeza večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
What is Respreeza and what is it used for? 
Kaj je zdravilo Respreeza in za kaj se uporablja?
It is not intended to provide practical advice on how to use Respreeza. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What are the risks associated with Respreeza? 
Kakšna tveganja so povezana z zdravilom Respreeza?
The decrease in lung density after 24 months was around 2.6 g/l in patients who received Respreeza, compared with a decrease of around 4.2 g/l in patients receiving placebo. 
Zmanjšanje pljučne gostote v 24 mesecih je bilo pri bolnikih, ki so prejemali zdravilo Respreeza, približno 2,6 g/l, pri bolnikih, ki so prejemali placebo, pa približno 4,2 g/l.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Respreeza have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Respreeza upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The most common side effects with Respreeza (which may affect up to 1 in 10 people) are dizziness, headache, dyspnoea (shortness of breath) and nausea. 
Najpogostejši neželeni učinki zdravila Respreeza (ki lahko prizadenejo največ 1 osebo od 10) so omotica, glavobol, dispneja (kratka sapa) in navzeja (slabost).
Subsequent infusions can be given by a caregiver or by the patient. 
Pozneje lahko zdravilo infundira negovalec ali bolnik.
For more information about treatment with Respreeza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Respreeza preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Allergic reactions were the main safety concern with Respreeza, but advice on how to manage this risk has been included in the product information. 
Pri zdravilu Respreeza je bil glavni varnostni zadržek alergijska reakcija, vendar so v informacije o zdravilu vključili nasvet o tem, kako obvladovati to tveganje.
Why is Respreeza approved? 
Zakaj je bilo zdravilo Respreeza odobreno?
Respreeza is used to slow down damage to the lungs in patients with severe disease. 
Zdravilo Respreeza se uporablja za upočasnitev poškodbe pljuč pri bolnikih s hudo boleznijo.
Because of the risk of severe allergic reactions, Respreeza must not be used in patients who are lacking IgA, a protein in the blood, and who have developed antibodies against it because these patients are more prone to allergic reactions. 
Zaradi tveganja hudih alergijskih reakcij se zdravilo Respreeza ne sme uporabljati pri bolnikih s pomanjkanjem beljakovine v krvi, imenovane IgA, in tistih, pri katerih so se razvila protitelesa proti njej, saj so ti bolniki bolj nagnjeni k alergijskim reakcijam.
For practical information about using Respreeza, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Respreeza naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For the full list of all side effects and restrictions with Respreeza, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Respreeza glejte navodilo za uporabo.
Lung density is an indicator of the extent of lung damage: the bigger the decrease in lung density, the greater is the damage to the lung. 
Pljučna gostota je pokazatelj obsežnosti pljučne poškodbe: večje kot je zmanjšanje pljučne gostote, večja je poškodba pljuč.
In the study, Respreeza was compared with placebo (a dummy treatment) and the main measure of effectiveness was the decrease in lung density. 
V tej študiji so zdravilo Respreeza primerjali s placebom (zdravilom brez zdravilne učinkovine), glavno merilo učinkovitosti pa je bilo zmanjšanje pljučne gostote.
Respreeza human alpha1-proteinase inhibitor 
Respreeza humani zaviralec alfa1-proteinaze
Respreeza is available as a powder and solvent to be made into a solution for infusion (drip) into a vein. 
Zdravilo Respreeza je na voljo v obliki praška in vehikla za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
Respreeza is a medicine used in adults with alpha1-proteinase inhibitor deficiency, an inherited disorder that can cause lung problems such as increasing shortness of breath and which may also affect the liver. 
Respreeza je zdravilo, ki se uporablja pri odraslih s pomanjkanjem zaviralca alfa1-proteinaze, tj. dedne motnje, ki lahko povzroči težave s pljuči, kot je slabšajoča kratka sapa, in lahko prizadene tudi jetra.